Tailwinds' Take: Scientists of this caliber don't join SABs unless there's something exciting going on. We eagerly anticipate the release of Non-Human Primate data sometime (hopefully) soon. RICHMOND, British Columbia &  GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company...
Tailwinds' Take: Great news! xB3 is poised to be a game-changing platform for treatment of CNS diseases. Still early stage, but the opportunity deserves a higher valuation. When they list in the US (later this year?), Bioasis stock could...
Tailwinds' Take: having a manufacturing partner is a key step towards clinical development of their drug candidates. With their recent financing, which we believe had large insider participation, behind them, we would expect to see more press releases out...
Quarterly earnings season is the four times each year in which companies give investors an inside look as to what's going on. They not only reveal their sales and profits, but, typically, they provide guidance (either specifically or in...
Tailwinds' Take: the closing of this private placement is a key catalyst for Bioasis shares. We have been adding in the Tailwinds portfolios and look forward to seeing how details concerning the level of insider participation. If insiders were...
When I removed Bioasis from the Tailwinds Select Portfolio, it was with great reluctance. This is a Company that I believe has groundbreaking, lifesaving, technology. The management team is strong and the board is outstanding. All the pieces were...
VANCOUVER, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company with a proprietary blood-brain barrier platform delivery technology focused on development of therapeutics for the treatment of brain cancers and neurodegenerative diseases, today announced a key...
VANCOUVER, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis TECHNOLOGIES, INC . (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company with a proprietary blood-brain barrier platform technology focused on development of therapeutics for the treatment of brain cancers and neurodegenerative diseases, today announced that Dr. Deborah...
Tailwinds' Take: new CEO Mark Day continues to build out a professional team as they look to take biOasis to the next level. We continue to believe that, for early stage biotech, this is the best risk/reward we have...
Vancouver, BC, BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) today announced the voting results from its Annual General Meeting held on Sept. 21, 2017 in Vancouver, British Columbia. The total number of shares represented in person or by proxy at the...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.